After insecticidal soap to fight malaria, it is the turn of a new vaccine to emerge. American researchers at the Sanaria laboratory are delighted with the results of a first clinical trial of this vaccine, made from weakened parasites responsible for malaria and transmitted by the female of the Anopheles mosquito.
A total of 40 people aged 20 to 44 participated in the trial, the results of which were published by the journal Science. Of the nine people who received a high dose of the vaccine, six achieved 100% protection against this infectious disease the deadliest in the world, which mainly affects children under five and pregnant women.
“Although we are still in the early stages of development, we believe that this vaccine will eliminate malaria, said Stephen Hoffman, CEO of Sanaria, quoted by AFP.” Scientists have been working to produce a malaria vaccine since then. thirty years and now these results show that we have a safe, injectable vaccine that can save millions of lives. “
However, some scientists are quite cautious about this novelty. Indeed, the vaccine will have to face many difficulties before it can be marketed on a large scale. Not only is the research not complete and future clinical trials will have to determine the duration of immunization and its effectiveness against variants of the parasite, but its marketing may be costly and problematic. Indeed, the vaccine must be stored in liquid nitrogen and injections into infants may be complicated to perform, say the researchers.
